Clinical study document search, explained.

Clinical trial document search explained: one question, many files, and an answer that moves

The path of one VLT-302 question, from the asking to the correction

1. Someone asks in plain wordsA colleague needs the target sample size for a slide. A CRA asks about the Week 16 window on the way to a site.
2. The sources are foundProtocol, amendments, plans, logs, minutes, trackers, and this morning's CTMS and EDC extracts, within what this person may see.
3. Every statement of the fact is dated and comparedFour statements of the sample size turn up, from February to September. Two say 600 and two say 640. This is the step this guide is about.
4. The answer comes back with its source640, as of September 18, analysis plan v3.0, section 9.2, page 21, with the disagreement stated beside it.
5. The older statement goes to its ownerThe study manager decides: correct it, or record why the difference is fine. If the answer matters, it is filed as a record.

The people, trial and figures in this example are fictional.

Why a filed protocol can be wrong, and three more surprises in trial documents

TMF, as-of date, superseded and out of date: four words for this work

Fourteen terms are defined in the one-page summary.

How much a Phase 3 study has to keep straight: sites, visits, procedures and millions of data points

In shortPhase 3 is the large, late-stage trial before a company applies for approval. Tufts benchmarks describe its average protocol: about 82 sites in 14 countries, 21 planned visits, 266 procedures and 3.45 million data points. Each of those details is written down in more than one place. The size of the job is why a question that sounds simple can take most of an hour.

Those averages come from a working group of 20 companies and contract research organizations (CROs, firms hired to run trial work), so treat them as a guide to scale. A given sponsor, the company that runs and pays for a trial, will have its own figures.4 The direction is clear, though. For Phase 2 and Phase 3 protocols combined, the mean count of procedures rose by two-thirds between 2009–2012 and 2017–2020.4 Every added country brings an ethics committee and language versions, and often local amendments.

How many documents sit in a trial master file

There is no standard published figure. One vendor white paper says a Phase 3 at 264 sites in 12 countries "might conservatively be expected to generate 5000 to 10,000 TMF documents", before counting participant-level records such as case report forms.5

That comes from a company selling TMF services and is an estimate. The fictional study in this guide holds 1,284 documents, with 142 superseded versions among them, which is deliberately on the small side. Count your own by exporting the index from your TMF: it takes minutes and gives you a defensible number.

Where the same fact gets written down

The volume matters less than the repetition. Each document is written for a different reader, so the same value gets stated many times, and each statement has its own owner, version and date.

Protocol amendments and version control: what one approved change leaves out of date

In shortThree in four protocols are amended, and most amendments cannot be avoided. Getting one approved at every site takes about 260 days on average. During that time the protocol, and everything that restates it, moves at different speeds. Nobody's job description includes finding every document that now disagrees.

The 2024 Tufts paper also separates what is under a sponsor's control from what is not. It reports 77% of amendments deemed unavoidable, with requests from regulators and changes in study strategy as the top reasons.2 So the answer to stale documents cannot only be "amend less". Oncology (cancer) trials are amended most: 91.1% of oncology protocols had an amendment, with a mean of 4.0, against 72.1% and 3.0 for other protocols.6

The months an amendment takes to reach every site

The time an amendment takes is the time a study spends inconsistent. Tufts measured about 260 days from identifying the need to amend until the last oversight approval, and 215 days when sites worked from different versions.2

A 2023 article on the same data adds that the first participant was re-consented 89 days after final internal approval, and that about two-thirds of active participants were re-consented in protocols with a substantial amendment.7 It also found country-specific amendments in 44.8% of Phase 2 and 60.1% of Phase 3 protocols.7 So one trial can hold two current versions in two countries, with both correct.

Why ICH M11 may help the protocol, and leaves the copies alone

The International Council for Harmonisation (ICH) is where regulators and drug makers agree shared standards. Its M11 is a new structured template for the protocol, adopted in November 2025. The US Food and Drug Administration (FDA) published it as guidance in May 2026.8 EMA's version took effect on June 11, 2026.9

Its template carries a protocol synopsis and a table of amendment changes, so over time the synopsis may be drawn from the same structured content as the body. That should help with a mismatch inside the protocol. In our reading, it does little for a scheduling guide, a printed card or a spreadsheet, which sit outside the template.

Newest, governing or in force at this site: three questions a study answer has to keep apart

In short"Use the latest version" hides three separate questions. Which statement is newest? Which document governs when two disagree? Which version is in force at this site today? They often have different answers, and a study answer that blurs them can send a site the wrong instruction with complete confidence.

Take the first example from the top of this page. The analysis plan's 640 is the newest statement and tells the team what they are working toward. It does not change what regulators and ethics committees have approved.

In the US, a Phase 3 sponsor must submit a protocol amendment for a change that significantly affects "the scope of the investigation, or the scientific quality of the study", and the listed examples include "any significant increase in the number of subjects under study".10 So a careful answer says all of it: the target is now 640, the protocol still says about 600, Amendment 4 will correct it, and here is what that means for you.

The seven sites shown are the ones with participants still to re-consent. Of 88 sites, 81 have approval. The seven still waiting are the ones in Japan, Brazil, South Korea and elsewhere with no bar to draw.

Three written rules for which document wins when two disagree

Teams settle disagreements in different ways, and each one is defensible when written down:

• The newest approved statement. Good for targets and planning numbers, where the team needs to know the current intent.
• The protocol first, then the newest plan. Good for anything a site must do, because the protocol is what the ethics committee approved.
• The system of record for live numbers. For counts, the EDC or CTMS at a stated time beats any tracker. A tracker can still be right about something the system has not caught up on, as you will see in section 07.

The failure to look out for is a tool, or a person, applying the first rule to a question that needs the second. A CRA who asks "what does this site do at Week 16?" needs the version in force at that site. Ask any search tool how it handles this before you trust its dates.

Rules on trial records in 2026: ICH E6(R3), the EU trial master file guideline, Part 11 and the UK's new regulations

In shortGood clinical practice (GCP), the quality standard for running trials on people, changed in the last two years. ICH E6(R3), its current text, is final at ICH, its Annex 2 reached final form in June 2026, and the UK's amended clinical trial regulations took full effect in April 2026. All of them ask for records that are version controlled, findable and available on request. None of them requires an AI search tool, and all of them apply to one if you use it.

At FDA, Annex 2 is still a draft, published December 30, 2024, with its comment period reopened March 13, 2025. The Federal Register showed no final notice on November 3, 2026, and FDA's final E6(R3) page does not mention it.12,14

What each rule asks of a study's records and searches

CTMS, EDC, trackers or the protocol: which source answers which clinical study question

In shortDocuments hold the rules. The CTMS holds what the team did. The EDC holds what happened to participants. Trackers hold what somebody needed last Tuesday. Each runs on its own clock, so the same question asked of two sources on the same morning can give two honest numbers.

How study records differ, and how each one misleads

E6(R3) expects you to know where your essential records are: sponsors and investigators "should maintain a record of where essential records are located".1 That record, if you have it, is the map of what a search has to read. It also helps with something people miss: records may be "maintained in or referred to from" a repository, so a study's essential records may not all sit in one piece of software.1

Sample size, visit windows and re-consent counts, worked through with the numbers

In shortFollow four real kinds of study question through the fictional VLT-302 trial. Each one shows why the number needs a date beside it and how you check it: a blinded sample-size review, a two-day gap in a visit window, a re-consent count that differs by three, and a measure of how old a stale statement is.

Why VLT-302's target moved from 600 to 640 without anyone seeing results

A sample size rests partly on a guess about the population, here the share of people who drop out early. A blinded review checks that guess using pooled data, with nobody seeing results by treatment arm. ICH E9 says sample size re-estimation is possible "without unblinding data or making treatment comparisons".19 FDA's adaptive designs guidance calls this "the most widely used category" of adaptation on pooled outcomes.20

VLT-302 assumed 8% of participants would stop early. By August 31, 57 of 483 randomized participants had stopped early: 11.8%. The arithmetic below is ours, for illustration. The real sizing rests on statistical power for the key endpoint, meaning the chance of detecting a real effect on the trial's main measure, as set out in the analysis plan.

One number changed for a good reason, so the older value now sits in a superseded plan, a protocol synopsis, and any slide built in the last six months. Only the first of those is harmless.

Visit window deviations: the two days between a ±3 and a ±5 Week 16 window

A visit window is the range of days around a target day when a visit may happen. Week 16 here means Day 113. Protocol v4.0, page 18, says ±3 days, so Day 110 to Day 116. The site scheduling guide, written in January before Amendment 2 narrowed the window, still says ±5, so Day 108 to Day 118.

In the example, 23 of 418 Week 16 visits in September fell outside the window: 5.5%, 15 late and 8 early, with 11 of them at three sites. The example shows the guide and the visits side by side. It does not prove the guide caused them, and neither would any real file without asking the sites. That is a good habit to keep: a stale document gives you a reason to ask.

Re-consent tracking: reconciling a count when EDC says 67 and the tracker says 64

Re-consent means asking people already in the trial to confirm they still agree, after new information arrives. E6(R3) says participants should be "informed in a timely manner if new information becomes available" that may matter to their willingness to continue.1 US rules list a matching statement among the extra consent elements given "when appropriate": that significant new findings will be provided.21 Amendment 3 requires a signature on consent form v5.0 at the next scheduled visit after the site's ethics approval. Counting who owes one takes four steps.

The CRAs' tracker says 64. The EDC says 67. Neither is wrong: three participants at Site 214 signed on paper on October 2. The tracker has them and the EDC does not, because nobody has entered them yet. The right answer gives both numbers, says why they differ, uses the system of record until the entry is made, and raises the entry as a task.

Sixty-one more participants at seven sites will join the list when those sites receive approval. The sample counts 499 on study out of 512 randomized, and it does not say how people who stopped early are counted, so do not work one number out from the other.

How old is a stale statement: counting back from the newer document

The measure is plain date arithmetic: the date of the newer approved statement minus the date of the older. It tells you how long the older one could have misled someone, and it helps you decide what to chase first. Age alone does not rank them, though. Thirty-five days on a sample size matters less to a site today than 206 days on a visit window, which sites use every week.

How a clinical trial search can break the blind, and what keeps it safe

In shortIn a blinded trial, the study team must not learn who received what. Anything that reads across systems inherits every access those systems allow, so a search that joins data carelessly can expose treatment. The fix is to decide what is never connected, before connecting anything, and to apply the asker's own access on every question.

Blinding keeps knowledge of treatment away from anyone whose judgment it might bend. ICH E6(R3) now places it in data governance and lists where it is at risk: "the design of systems, management of users' accounts, delegation of responsibilities with respect to data handling and provision of data access at sites, data transfers, database review prior to planned unblinding".1 People who work with sites "should not have access to unblinding information except when justified by the trial design".1 Sharing records calls for "careful consideration" where blinding is involved.1

The line sits earlier than many people assume. FDA's 2024 draft guidance on data monitoring committees says that reporting data with codes (treatment groups labeled A and B) "can be informative and should be best treated as unblinded".22 A search that groups any table by a field called "arm", "cohort" or "group" could therefore cross the line without naming a single treatment.

Four safeguards to have in place before a search reads any study data

Inspection readiness and the TMF: the version-control findings EMA and FDA inspectors write up

In shortEMA's latest GCP report puts essential documents at the top of its sub-categories and names "lack of version control" among common findings. FDA's list of common observations includes protocol deviations and informed consent. Neither regulator separates findings caused by a stale document, so the link is one you have to measure in your own files.

Since a March 2025 decision, this report counts only major and critical findings, so the total should not be compared with earlier years.23

EMA's report gives examples under essential documents, and they describe this guide's subject: "Lack of version control and document management: missing version control of worksheets, informed consent forms, inconsistencies between protocol and investigator brochure; no formally documented process for TMF quality control."23 It also lists lack of access at the trial site to electronic systems holding essential documents, and incomplete or poorly maintained files.23

What FDA's inspection data says about investigators and sponsors

FDA's bioresearch monitoring program classified 609 clinical investigator inspections in fiscal 2024: no action indicated in 484, voluntary action in 110, and official action in 15.24 Its common investigator observations include failure to follow the investigational plan and protocol deviations, inadequate study records, and inadequate subject protection and informed consent issues.24

For sponsors and CROs, they include failing to ensure proper monitoring and that the study follows the protocol.24 FDA lists these without counts, so this is a list of what recurs. A 2022 trade article says about 30% of warning letters concern failure to follow the investigational plan, without giving its year or base; treat that as a rough guide.25

The errors behind version findings, and why they happen

Protocol deviations and amendment costs: the published figures around out-of-date study documents

In shortNobody publishes what a stale study document costs. The nearest published numbers are the cost of an amendment and the deviations a Phase 3 trial carries. They frame the size of the problem and leave you to count your own share.

E6(R3) asks sponsors to decide which deviations are "important": those that may significantly affect the reliability of the data or a participant's rights, safety or well-being.1 A visit two days outside a window will often be minor, unless it falls on the visit that measures the main result. A consent signed on the wrong version touches a participant's rights, so in our reading many sponsors would class it as important, and it stays on the record of the trial.

Where the trend points: more amendments, more plans, structured protocols, early AI use

• More to keep straight. Amendments per protocol rose 60% between the two Tufts studies.2
• A faster-moving rulebook. Risk-based monitoring, which aims checks at the greatest risks, under E6(R3) means more plans that change midstream, each with a value that gets repeated. That point is our reading.
• Structured protocols. ICH M11 should make some protocol content machine-readable over time.8
• Early and uneven AI use. As of late 2024, 11% of nearly 80 pharma and biotech companies had AI fully implemented in trial work, according to a trade report on a WCG survey.27

AI in clinical trial operations: what search can do with study files, and what FDA and EMA expect

In shortLanguage models, the AI behind chat assistants, can read a study's files by meaning, join them with data and show the passage behind each claim. They also make mistakes even when given the right passage. Regulators are writing rules that scale with how much a person relies on the output. A cited answer that a person can open and check sits at the low end of that scale, provided the person opens it and reads it.

Five jobs called "AI in clinical trial operations", and how far each one has to be trusted

What FDA, EMA and others say about AI as of November 2026

The limits of retrieval: errors persist when the passage is right

Retrieval means fetching the relevant passage and showing it to the model. It reduces invention but does not end it. Stanford researchers tested commercial legal research tools built on retrieval and measured hallucinated, meaning invented, answers "between 17% and 33% of the time".38 That is law, and the tools have changed since. A 2025 clinical preprint on guideline questions found that "errors persist even when authoritative passages are provided".39

We found no published error rate for clinical study document search. So a team has to measure its own, with questions whose answers it already knows.

The failure that matters most in this work is a real passage from the wrong version, cited correctly. It reads well and points to a real page. Only a check of the date and the version catches it, which is why a good answer leads with both.

What stays with people when study search is automated

• Which document governs, as a rule written down in advance.
• Whether a difference is real, or explained, or something to correct.
• Any clinical judgment. A medical monitor answers the investigator. Search finds the rule and the page.
• The record. An answer stays a working note until a named person files and signs it.
• The file itself. The TMF stays the system of record. Search reads it and leaves it unchanged.

How study teams answer questions today: the study manager as the study's human index

In shortA question reaches the person most likely to know. They open the TMF, find a version, find a page, pull an extract, check a tracker and write back. Nobody times it. One study team's estimate is 30 to 60 minutes when a question crosses documents and data, and about three days of a study manager's week. Whether anything else is now out of date gets noticed by luck.

Study manager, CRA, medical monitor: who asks and who answers on a clinical trial

Six hand-offs behind one answer about a visit window

Where a study manager's three question-answering days go

From shared FAQs to eTMF search: four ways study teams find answers now

A team can also pay a CRO to run the TMF and answer through it. The responsibility stays with the sponsor. E6(R3) says arrangements must be made for access to and management of essential records when activities are transferred to a service provider, and that records should be available on request.1

"What is the target sample size?": from the search bar to a fact card, a flag and a correction

In shortThis is the example from the top of the page, inside the product. Lena Ortiz, the study manager on VLT-302 at Northwind Bio, types her question. Agents, pieces of software that each do one defined job, find every statement of the fact, date them, and return a fact card: 640, as of September 18, with the protocol synopsis flagged as still saying 600. One click sends the correction to the Amendment 4 list, and the older statement waits on a list until its owner deals with it.

1

One search bar over the whole study

It is Wednesday, October 7, 2026. The search reads 1,284 study documents, the CTMS extract from 6:00 a.m., the EDC from 5:30 a.m., blinded IRT data, and four trackers and logs. A green note says the answers use blinded data only, within Lena's site access.

Her first answer from earlier this morning is already on screen, and the panel on the right lists what is out of date in the study files today.

2

Five agents run in view

Lena asks: "What is the target sample size?" The question router sends it to the VLT-302 documents. The document reader finds 9 passages and 4 statements of the fact. The data analyst reads the enrollment extract. The version checker dates every statement. The answer writer starts last, and each step shows its time.

3

A fact card: 640, as of September 18

The answer leads with the number: 640 participants to randomize, 3:1, with 480 on veltrimab and 160 on placebo. Beside it, the as-of date and source: statistical analysis plan v3.0, section 9.2, page 21. Under that, progress: 512 randomized so far, 80% of the target.

Every approved statement sits on one line, oldest to newest, and the passages below show the exact sentences.

Read the flag as carefully as the number. The card says what the current target is and shows where the file disagrees. What a site may do today still follows the approved protocol, which is why the correction goes in an amendment. A sponsor who prefers the protocol to win can set that: the setting appears in section 14.

4

The flag: the protocol synopsis still says 600

Protocol v4.0 was approved on August 14, 35 days before the plan. The blinded review of September 11 found 11.8% of participants had stopped early across both groups, 57 of 483 randomized by August 31, against 8% assumed. Decision D-024 on September 16 raised the target and put the synopsis correction in Amendment 4.

"Open the older passage" shows page 3, marked out of date, with the newest approved statement named above it.

5

One click puts it on the Amendment 4 list

Lena clicks "Add to the Amendment 4 list". A follow-up is created in her name, due October 21: add the synopsis sample size, 600 to 640, to the change list. It traces back to question Q-1044. On the right, the statement moves from Open to Correction asked.

6

Every out-of-date statement in one list

Each morning at 6:30 a.m., every document is re-checked: today 1,284 documents, 6 new since yesterday. Five statements are listed, each with the fact, the older wording, the newest approved wording, how much older it is, its owner and its status. They run from a CRA checklist that still says "verify 100% of pages" to a pharmacy card already corrected and sent to all 88 sites.

7

Side by side: the site guide that is 206 days behind

Sam Patel, a CRA covering the UK and Canada, asked about the Week 16 window at 7:31 a.m. Opened side by side, the guide says ±5 days and the protocol says ±3. The note explains that the guide came before Amendment 2 and that sites still print visit cards from it. Lena can mark it explained, or ask for the correction.

Re-consent, deviations, sources and settings: the rest of the study search on screen

In shortOne question is the story. These screens show the rest: a re-consent answer that joins a rule with three data sources, a deviation count where the sources disagree and a person decides, filing to the TMF with an e-signature, the follow-ups, the sources including the three never read, a usage dashboard, and the settings where your own rules live.

Select any screen to open it larger. The companies, people, sites and figures are fictional, and the document text on the screens is the sample study's own.

Six agents route, read, query, date, answer and plan; the study manager checks and signs

In shortEach agent has one job and limits it does not cross. None of them edits a source, files a record or decides a correction. Five run on each question, and the follow-up planner works from the finished answer. People check what is uncertain, and the study manager files with an e-signature.

From question router to follow-up planner: the six study search agents

Lena checks, Lena signs: what stays with the study team

• Two sets of eyes. Agents propose and people decide. A CRA can ask; the study manager checks and files. You choose who may file: the study manager alone, or the medical monitor as well.
• A person checks what is uncertain. An answer below 0.90 confidence, or one where sources disagree without an explanation, shows as "Needs your check".
• Signed when filed. Filing records the question, answer, sources, query and data time as a study note, signed with its meaning. These are controls that support your compliance with 21 CFR Part 11 and EMA's guideline on computerised systems in clinical trials; your validation and use decide compliance.17,15
• Read-only, in place. Every search, flag, follow-up and status change is on the audit trail. No source document or system is edited.
• Enterprise ready. Roles and site access per study, the blinding rule locked, connections to your TMF, CTMS and EDC, and an audit trail you can export. Botminds' credentials are SOC 2 Type II audited and information security managed to ISO 27001.

The people on the VLT-302 screens

Protocol, plans, CTMS and EDC in; fact cards, flags and signed study notes out

In shortThe solution reads what a study already runs on and returns answers a person can check. It connects to your own systems by category, and everything stays read-only. Outcome numbers here are design targets and estimates to test on your own study.

Systems a study search rollout connects to

For each, check whether it has an API, a file feed or an export, who owns it, and who signs the blinded view.

Study search in numbers: a design target, an estimate and sample data, each labeled

Going live means building it from your requirements and study files, passing every quality check, and running it on your own study first.

What slow answers and stale documents cost your clinical operations team

In shortStart from your own costs, because the numbers that matter here are unpublished. A few published figures show the scale: how long sites run on mixed versions, what an amendment costs, and what inspectors keep finding.

How to time your own study questions in one week

What a slow answer costs that no spreadsheet shows

What faster study answers return when you count hours, amendments and the tool's yearly cost

In shortPut in your own numbers. The calculator asks how many questions your teams handle, how many cross documents and data, how long each kind takes now and after, and what the tool and your validation cost a year. Every default is an assumption to replace, and hours released only count if you decide what they are for.

Answer time, correction sweeps, deviations and audits: where study search saves

Questions a week, minutes per answer and your hourly cost

A portfolio team with several Phase 3 studies can clear this. A team with one small study may find the hours do not justify a purchase, and should say so before buying anything. For that team, the case, if there is one, rests on stale statements found and on the inspection record.

Is your study team ready for document search? Eight questions on questions, versions, blinding and ownership

In shortScore your team from 0 to 2 on eight questions. A low score says what to fix first, usually the map of where your records are and who decides which document wins. A ninth question has no score, and it may be the most useful one.

What your score means: build the baseline, pilot on one study, or plan the portfolio

A 0 on blinded extracts, question 6, holds you back at any total. Fix that first.

Questions for any clinical trial search vendor: versions, the blind, access, audit trail and proof

In shortAsk us too. The questions that separate one tool from another are about versions, the blind and what happens when the tool is wrong. A demonstration on a vendor's clean sample answers none of them. Ask to see it on your own study.

Testing study document search on one running Phase 3: a 12-week pilot with known answers and planted contradictions

In shortPick one running study with at least one amendment. Time a baseline, write a test set whose answers you know, plant a few contradictions, try to break the blind, then run the tool beside your team for a month. Decide on measured results, and write down the failures too.

The measures that decide a study search pilot

Clinical trial document search, TMF search and protocol questions answered

In shortThe questions study teams and buyers search for, each answered on its own.